Short communicationEffect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists
References (10)
- et al.
Chronic treatment with levodopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]-spiperone binding
Brain Res.
(1986) - et al.
Behavioral and biochemical effects of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys
European J. Pharmacol.
(1988) - et al.
Dopaminergic mechanisms in hemiparkinsonian monkeys
Neurology
(1987) - et al.
A primate model for parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6 tetrahydropyridine
- et al.
Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity
Science
(1977)
Cited by (83)
Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys
2014, Experimental NeurologyCitation Excerpt :In the pre-commissural striatum, D1 receptors are reported to remain unchanged after exposure to MPTP (Aubert et al., 2005; Calon et al., 1995) and to increase with l-DOPA (Aubert et al., 2005; Guigoni et al., 2005; Rioux et al., 1997). On the contrary, no change (Alexander et al., 1993; Graham et al., 1993) or a decrease is observed in the post-commissural striatum (Gagnon et al., 1990; Morin et al., 2014) after l-DOPA treatment. In the present study, we observed significant decreases in the post-commissural D1 receptor specific binding after MPTP in all subdivisions of the striatum.
Modeling dyskinesia in animal models of Parkinson disease
2014, Experimental NeurologyCitation Excerpt :Denervation-induced supersensitivity of DA receptors is generally recognized as a plausible mechanism of LID. Post-mortem studies have shown that striatal DA receptors particularly of the D2 subtype were increased in PD patients (Bokobza et al., 1984; Guttman et al., 1986; Lee et al., 1978), while both D1 and D2 DA receptor subtypes were increased in MPTP-lesioned monkeys (Bedard et al., 1986; Falardeau et al., 1988; Gagnon et al., 1990; Graham et al., 1993). l-DOPA reverses this increase in humans (Guttman et al., 1986; Lee et al., 1978) and monkeys (Berretta et al., 1997; Falardeau et al., 1988; Gagnon et al., 1990).
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys
2014, NeuropharmacologyCitation Excerpt :As compared to D1 receptor, autoradiography studies on D2 receptors show more consistent results. Levels of D2 receptor in the striatum were reported to be unchanged (Calon et al., 1995; Gagnon et al., 1995; Goulet et al., 1996; Pifl et al., 1992) or increased with MPTP in monkeys (Alexander et al., 1993; Falardeau et al., 1988; Gagnon et al., 1990, 1995; Graham et al., 1990; Graham et al., 1993; Guigoni et al., 2005) and in untreated PD patients (Lee et al., 1978). Such DA denervation-induced increase in the expression of D2 receptor was shown to be reversed with the administration of l-DOPA (Alexander et al., 1993; Gagnon et al., 1990; Graham et al., 1993) or has no influence (Calon et al., 1995; Guigoni et al., 2005).
Therapy adherence issues in Parkinson's disease
2010, Journal of the Neurological SciencesCabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism
2008, Behavioural Brain ResearchEarly administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats
2005, Experimental Neurology